Open Payments

Osf Heart Of Mary Medical Center

Type
Teaching hospital
Where
Urbana, IL
Medicare CCN
140113
Received
$1,184,435 in 246 records, 2025 ($131,407 general, $1,053,027 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2025General payment19$131,407
2025Research payment227$1,053,027

By company

CompanyRecordsAmountYears
UCB SA2$391,8172025
Alkermes, Inc.152$242,3782025
ABBVIE INC.25$149,7682025
Regeneron Pharmaceuticals, Inc.1$92,5402025
Ardelyx, Inc.20$54,9732025
SANOFI US SERVICES INC.12$53,9532025
E.R. Squibb & Sons, L.L.C.1$47,5752025
Davol Inc.1$32,2342025
Takeda Pharmaceuticals U.S.A., Inc.3$21,0002025
Vifor Pharma, Inc.2$19,0152025
Vifor (International) Ltd.1$19,0002025
Penumbra, Inc.1$13,7002025
OCCLUTECH US LLC1$13,0592025
GENZYME CORPORATION2$9,7202025
Siemens Medical Solutions USA, Inc.4$4,0642025
Smith+Nephew, Inc.1$3,0002025
Organogenesis Inc.1$3,0002025
VERTEX PHARMACEUTICALS INCORPORATED1$3,0002025
Linde Gas & Equipment Inc.6$2,7722025
Stryker Corporation2$2,7562025
Biogen, Inc.1$2,0002025
Surmodics, Inc.2$1,6252025
Novo Nordisk Inc1$6502025
Cochlear Americas1$4632025
Haemonetics Corporation1$2252025
AstraZeneca UK Limited1$1422025

By nature of payment

NatureRecordsAmount
Research payment227$1,053,027
Grant3$109,540
Space rental or facility fees (teaching hospital only)13$18,647
Debt forgiveness2$3,035
Long term medical supply or device loan1$184

Records

DateCompanyAmountNatureFormProductStudyYear
2025-12-31Stryker Corporation$2,572Debt forgivenessCash or cash equivalent2025
2025-12-31ABBVIE INC.$303Research paymentIn-kind items and servicesRINVOQ Biological, IMMUNOLOGYA Phase 3 Multicenter Study to Evaluate Efficacy, Safety, and Pharmacokinetics of Upadacitinib with Open-Label Induction2025
2025-12-31Stryker Corporation$184Long term medical supply or device loanIn-kind items and servicesLIFEPAK 20 and LIFEPAK 20e defibrillator/monitors Device, EMS2025
2025-12-23Alkermes, Inc.$70Research paymentIn-kind items and servicesA Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALK2025
2025-12-10Alkermes, Inc.$574Research paymentCash or cash equivalentA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-12-10Alkermes, Inc.$500Research paymentCash or cash equivalentA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-12-05Alkermes, Inc.$500Research paymentCash or cash equivalentAn Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of 2025
2025-12-04AstraZeneca UK Limited$142Research paymentCash or cash equivalentIMFINZI Biological, OncologyAn Observational Multi-center Study to Evaluate Real-World Treatment Outcomes of Durvalumab-based Regimens in Hepatobili2025
2025-12-04Alkermes, Inc.$38Research paymentIn-kind items and servicesAn Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of 2025
2025-12-04Alkermes, Inc.$27Research paymentIn-kind items and servicesAn Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of 2025
2025-12-02ABBVIE INC.$845Research paymentCash or cash equivalentRINVOQ Biological, IMMUNOLOGYStudy to Assess Adverse Events Change in Disease Activity and How Oral Upadacitinib Moves Through the Body of Pediatric 2025
2025-12-01Alkermes, Inc.$574Research paymentCash or cash equivalentAn Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of 2025
2025-11-24SANOFI US SERVICES INC.$750Research paymentCash or cash equivalentA double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic 2025
2025-11-19Takeda Pharmaceuticals U.S.A., Inc.$3,000Space rental or facility fees (teaching hospital only)Cash or cash equivalent2025
2025-11-10Alkermes, Inc.$12,200Research paymentCash or cash equivalentA Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALK2025
2025-11-10Alkermes, Inc.$2,820Research paymentCash or cash equivalentAn Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of 2025
2025-11-10Alkermes, Inc.$2,500Research paymentCash or cash equivalentA Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALK2025
2025-11-10Alkermes, Inc.$2,100Research paymentCash or cash equivalentA Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALK2025
2025-11-10Alkermes, Inc.$2,000Research paymentCash or cash equivalentA Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALK2025
2025-11-10Alkermes, Inc.$441Research paymentCash or cash equivalentAn Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of 2025
2025-11-10Alkermes, Inc.$441Research paymentCash or cash equivalentAn Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of 2025
2025-11-10Alkermes, Inc.$200Research paymentCash or cash equivalentA Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALK2025
2025-11-08Linde Gas & Equipment Inc.$594Space rental or facility fees (teaching hospital only)In-kind items and servicesLGEREG081 Device, RESPIRATORY2025
2025-11-07Penumbra, Inc.$13,700Research paymentCash or cash equivalentIndigo System Device, Peripheral InterventionSTRIDE II2025
2025-11-05Alkermes, Inc.$4,300Research paymentCash or cash equivalentA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-10-30ABBVIE INC.$650Research paymentCash or cash equivalentRINVOQ Biological, IMMUNOLOGYStudy to Assess Adverse Events Change in Disease Activity and How Oral Upadacitinib Moves Through the Body of Pediatric 2025
2025-10-30Linde Gas & Equipment Inc.$594Space rental or facility fees (teaching hospital only)In-kind items and servicesLGEREG081 Device, RESPIRATORY2025
2025-10-30Linde Gas & Equipment Inc.$330Space rental or facility fees (teaching hospital only)In-kind items and servicesREQNOXBOX-I Device, RESPIRATORY2025
2025-10-25Novo Nordisk Inc$650Space rental or facility fees (teaching hospital only)Cash or cash equivalent2025
2025-10-20SANOFI US SERVICES INC.$4,856Research paymentCash or cash equivalentA double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic 2025
2025-10-20Ardelyx, Inc.$750Research paymentCash or cash equivalentIBSRELA Drug, GASTROENTEROLOGYTEN 01-304 -SAFETY AND EFFICACY PHASE 03 IN 12-18 YEAR OLDS2025
2025-10-20Ardelyx, Inc.$750Research paymentCash or cash equivalentIBSRELA Drug, GASTROENTEROLOGYAN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C2025
2025-10-17Vifor Pharma, Inc.$15Research paymentCash or cash equivalentRLY5016-208P2025
2025-10-08Alkermes, Inc.$4,475Research paymentCash or cash equivalentA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-10-08Alkermes, Inc.$4,475Research paymentCash or cash equivalentA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-10-08Alkermes, Inc.$898Research paymentCash or cash equivalentA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-10-08Alkermes, Inc.$433Research paymentCash or cash equivalentA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-10-02Ardelyx, Inc.$16,000Research paymentCash or cash equivalentIBSRELA Drug, GASTROENTEROLOGYPhase II Dose ranging safety and efficacy studying IBS-C patients 6-12 years old2025
2025-10-02Ardelyx, Inc.$3,150Research paymentCash or cash equivalentIBSRELA Drug, GASTROENTEROLOGYTEN 01-304 -SAFETY AND EFFICACY PHASE 03 IN 12-18 YEAR OLDS2025
2025-10-02Ardelyx, Inc.$2,320Research paymentCash or cash equivalentIBSRELA Drug, GASTROENTEROLOGYAN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C2025
2025-10-02Ardelyx, Inc.$750Research paymentCash or cash equivalentIBSRELA Drug, GASTROENTEROLOGYAN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C2025
2025-10-02Ardelyx, Inc.$750Research paymentCash or cash equivalentIBSRELA Drug, GASTROENTEROLOGYTEN 01-304 -SAFETY AND EFFICACY PHASE 03 IN 12-18 YEAR OLDS2025
2025-09-30ABBVIE INC.$585Research paymentCash or cash equivalentRINVOQ Biological, IMMUNOLOGYStudy to Assess Adverse Events Change in Disease Activity and How Oral Upadacitinib Moves Through the Body of Pediatric 2025
2025-09-26ABBVIE INC.$3,002Research paymentCash or cash equivalentStudy of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD)2025
2025-09-24Vifor (International) Ltd.$19,000Research paymentCash or cash equivalentRLY5016-208P2025
2025-09-24Vifor Pharma, Inc.$19,000Research paymentCash or cash equivalentRLY5016-208P2025
2025-09-24Surmodics, Inc.$125Research paymentCash or cash equivalentPROWL Registry Device, Pounce Thrombectomy System Retrospective RegistryPounce Thrombectomy System Retrospective Registry (PROWL)2025
2025-09-17Alkermes, Inc.$7Research paymentCash or cash equivalentA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-09-15GENZYME CORPORATION$7,270Research paymentCash or cash equivalentA Randomized, Double-blind, Phase 3 Study Comparing Efficacy and Safety of Frexalimab (SAR441344) to Placebo in Adult Pa2025
2025-09-09Siemens Medical Solutions USA, Inc.$1,632Research paymentCash or cash equivalentProBeam Proton Therapy System Device, OncologyFLASH Radiotherapy for the treatment of symptomatic bone metastases in the thorax.2025
2025-09-08Alkermes, Inc.$12,200Research paymentCash or cash equivalentAn Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of 2025
2025-09-08Alkermes, Inc.$4,475Research paymentCash or cash equivalentA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-09-08Alkermes, Inc.$2,500Research paymentCash or cash equivalentAn Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of 2025
2025-09-08Alkermes, Inc.$2,100Research paymentCash or cash equivalentAn Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of 2025
2025-09-08Alkermes, Inc.$2,000Research paymentCash or cash equivalentAn Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of 2025
2025-09-08Alkermes, Inc.$898Research paymentCash or cash equivalentA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-09-08Alkermes, Inc.$433Research paymentCash or cash equivalentA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-09-08SANOFI US SERVICES INC.$207Research paymentCash or cash equivalentRandomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab2025
2025-09-08Alkermes, Inc.$200Research paymentCash or cash equivalentAn Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of 2025
2025-09-04Biogen, Inc.$2,000GrantCash or cash equivalent2025
2025-09-04UCB SA$1,228Research paymentIn-kind items and servicesRystiggo Drug, NeurologyA randomized, double-blind, placebo-controlled, multicenter, phase 3, pivotal study with an open-lable extension period 2025
2025-09-03ABBVIE INC.$16,875Research paymentCash or cash equivalentStudy of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD)2025
2025-09-03Alkermes, Inc.$4,042Research paymentCash or cash equivalentA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-09-03Alkermes, Inc.$172Research paymentIn-kind items and servicesA Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALK2025
2025-09-03Alkermes, Inc.$131Research paymentIn-kind items and servicesA Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALK2025
2025-09-03Alkermes, Inc.$71Research paymentIn-kind items and servicesA Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALK2025
2025-09-03Alkermes, Inc.$51Research paymentIn-kind items and servicesA Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALK2025
2025-09-02ABBVIE INC.$8,294Research paymentCash or cash equivalentStudy of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD)2025
2025-09-02ABBVIE INC.$5,624Research paymentCash or cash equivalentRINVOQ Biological, IMMUNOLOGYStudy to Assess Adverse Events Change in Disease Activity and How Oral Upadacitinib Moves Through the Body of Pediatric 2025
2025-08-28ABBVIE INC.$27,845Research paymentCash or cash equivalentStudy of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD)2025
2025-08-28ABBVIE INC.$574Research paymentCash or cash equivalentStudy of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD)2025
2025-08-26ABBVIE INC.$715Research paymentCash or cash equivalentRINVOQ Biological, IMMUNOLOGYStudy to Assess Adverse Events Change in Disease Activity and How Oral Upadacitinib Moves Through the Body of Pediatric 2025
2025-08-25Ardelyx, Inc.$1,820Research paymentCash or cash equivalentIBSRELA Drug, GASTROENTEROLOGYAN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C2025
2025-08-20Alkermes, Inc.$1,000Research paymentCash or cash equivalentA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-08-19Takeda Pharmaceuticals U.S.A., Inc.$15,000GrantCash or cash equivalent2025
2025-08-18Alkermes, Inc.$500Research paymentCash or cash equivalentAn Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of 2025
2025-08-13Alkermes, Inc.$70Research paymentIn-kind items and servicesA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-08-11SANOFI US SERVICES INC.$9,200Research paymentCash or cash equivalentRandomized, Double-blind, Placebo-controlled, Parallel-group Phase 3 Study to Evaluate the Efficacy, Safety, and Tolerab2025
2025-08-11SANOFI US SERVICES INC.$3,000Research paymentCash or cash equivalentA double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic 2025
2025-08-11Alkermes, Inc.$2,878Research paymentCash or cash equivalentA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-08-06ABBVIE INC.$6,531Research paymentCash or cash equivalentStudy of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD)2025
2025-08-06Alkermes, Inc.$2,651Research paymentCash or cash equivalentAn Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of 2025
2025-08-06Alkermes, Inc.$1,754Research paymentCash or cash equivalentAn Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of 2025
2025-08-06Alkermes, Inc.$441Research paymentCash or cash equivalentAn Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of 2025
2025-07-31ABBVIE INC.$14,041Research paymentCash or cash equivalentStudy of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD)2025
2025-07-29Ardelyx, Inc.$1,537Research paymentCash or cash equivalentIBSRELA Drug, GASTROENTEROLOGYAN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C2025
2025-07-29Ardelyx, Inc.$500Research paymentCash or cash equivalentIBSRELA Drug, GASTROENTEROLOGYPhase II Dose ranging safety and efficacy studying IBS-C patients 6-12 years old2025
2025-07-28Alkermes, Inc.$3,880Research paymentCash or cash equivalentA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-07-25Alkermes, Inc.$68Research paymentCash or cash equivalentAn Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of 2025
2025-07-25Alkermes, Inc.$34Research paymentCash or cash equivalentAn Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of 2025
2025-07-21Alkermes, Inc.$1,196Research paymentIn-kind items and servicesA Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALK2025
2025-07-17Alkermes, Inc.$650Research paymentIn-kind items and servicesA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-07-10ABBVIE INC.$82Research paymentCash or cash equivalentStudy of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD)2025
2025-07-09Surmodics, Inc.$1,500Research paymentCash or cash equivalentPROWL Registry Device, Pounce Thrombectomy System Retrospective RegistryPounce Thrombectomy System Retrospective Registry (PROWL)2025
2025-07-08ABBVIE INC.$9,732Research paymentCash or cash equivalentStudy of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD)2025
2025-07-07Alkermes, Inc.$4,042Research paymentCash or cash equivalentA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-07-07Alkermes, Inc.$3,294Research paymentCash or cash equivalentA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-07-07Alkermes, Inc.$136Research paymentCash or cash equivalentA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-07-07Alkermes, Inc.$90Research paymentCash or cash equivalentA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-07-07Alkermes, Inc.$68Research paymentCash or cash equivalentA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-07-07Alkermes, Inc.$52Research paymentCash or cash equivalentA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-07-02ABBVIE INC.$12,749Research paymentCash or cash equivalentStudy of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn s Disease (Target CD)2025
2025-07-02SANOFI US SERVICES INC.$4,821Research paymentCash or cash equivalentA double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic 2025
2025-07-02ABBVIE INC.$390Research paymentCash or cash equivalentRINVOQ Biological, IMMUNOLOGYStudy to Assess Adverse Events Change in Disease Activity and How Oral Upadacitinib Moves Through the Body of Pediatric 2025
2025-07-01Ardelyx, Inc.$8,000Research paymentCash or cash equivalentIBSRELA Drug, GASTROENTEROLOGYAN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C2025
2025-06-30Haemonetics Corporation$225Space rental or facility fees (teaching hospital only)Cash or cash equivalentTEG6S HEMOSTASIS SYSTEM Device, DEVICES2025
2025-06-18Alkermes, Inc.$282Research paymentIn-kind items and servicesA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-06-18Alkermes, Inc.$231Research paymentCash or cash equivalentA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-06-18Alkermes, Inc.$200Research paymentIn-kind items and servicesA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-06-18Alkermes, Inc.$192Research paymentIn-kind items and servicesA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-06-18Alkermes, Inc.$162Research paymentIn-kind items and servicesA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-06-18Alkermes, Inc.$154Research paymentIn-kind items and servicesA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-06-18Alkermes, Inc.$127Research paymentIn-kind items and servicesA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-06-18Alkermes, Inc.$111Research paymentIn-kind items and servicesA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-06-18Alkermes, Inc.$109Research paymentIn-kind items and servicesA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-06-18Alkermes, Inc.$74Research paymentIn-kind items and servicesA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-06-18Alkermes, Inc.$74Research paymentIn-kind items and servicesA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-06-18Alkermes, Inc.$74Research paymentIn-kind items and servicesA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-06-18Alkermes, Inc.$68Research paymentCash or cash equivalentA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-06-18Alkermes, Inc.$68Research paymentCash or cash equivalentA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-06-18Alkermes, Inc.$51Research paymentIn-kind items and servicesA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-06-18Alkermes, Inc.$50Research paymentIn-kind items and servicesA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-06-18Alkermes, Inc.$47Research paymentIn-kind items and servicesA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-06-18Alkermes, Inc.$37Research paymentIn-kind items and servicesA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-06-18Alkermes, Inc.$34Research paymentIn-kind items and servicesA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-06-18Alkermes, Inc.$34Research paymentCash or cash equivalentA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-06-18Alkermes, Inc.$34Research paymentCash or cash equivalentA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-06-18Alkermes, Inc.$33Research paymentIn-kind items and servicesA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-06-18Alkermes, Inc.$32Research paymentIn-kind items and servicesA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-06-18Alkermes, Inc.$27Research paymentIn-kind items and servicesA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-06-18Alkermes, Inc.$27Research paymentIn-kind items and servicesA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-06-18Alkermes, Inc.$25Research paymentIn-kind items and servicesA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-06-18Alkermes, Inc.$25Research paymentIn-kind items and servicesA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-06-18Alkermes, Inc.$25Research paymentIn-kind items and servicesA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-06-18Alkermes, Inc.$16Research paymentIn-kind items and servicesA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-06-18Alkermes, Inc.$15Research paymentIn-kind items and servicesA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-06-18Alkermes, Inc.$12Research paymentIn-kind items and servicesA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-06-18Alkermes, Inc.$12Research paymentIn-kind items and servicesA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-06-18Alkermes, Inc.$8Research paymentIn-kind items and servicesA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-06-18Alkermes, Inc.$8Research paymentIn-kind items and servicesA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-06-18Alkermes, Inc.$5Research paymentIn-kind items and servicesA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-06-18Alkermes, Inc.$4Research paymentIn-kind items and servicesA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-06-18Alkermes, Inc.$2Research paymentIn-kind items and servicesA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-06-18Alkermes, Inc.$1Research paymentIn-kind items and servicesA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-06-18Alkermes, Inc.$1Research paymentIn-kind items and servicesA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-06-18Alkermes, Inc.$1Research paymentIn-kind items and servicesA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-06-16Siemens Medical Solutions USA, Inc.$1,500Research paymentCash or cash equivalentEclipse Treatment Planning System for External Beam Radiation Therapy Device, OncologyFLASH Radiotherapy for the treatment of symptomatic bone metastases in the thorax.2025
2025-06-11Alkermes, Inc.$8,402Research paymentCash or cash equivalentA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-06-11Alkermes, Inc.$6,399Research paymentCash or cash equivalentA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-06-11Alkermes, Inc.$3,286Research paymentCash or cash equivalentA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-06-11Alkermes, Inc.$979Research paymentCash or cash equivalentA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-06-11Alkermes, Inc.$433Research paymentCash or cash equivalentA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-06-05Smith+Nephew, Inc.$3,000Space rental or facility fees (teaching hospital only)Cash or cash equivalentSTRAVIX Biological, Extremities & Limb Restoration2025
2025-06-04Alkermes, Inc.$1,196Research paymentIn-kind items and servicesA Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALK2025
2025-05-29Alkermes, Inc.$1,045Research paymentIn-kind items and servicesA Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALK2025
2025-05-28Ardelyx, Inc.$2,110Research paymentCash or cash equivalentIBSRELA Drug, GASTROENTEROLOGYTEN 01-304 -SAFETY AND EFFICACY PHASE 03 IN 12-18 YEAR OLDS2025
2025-05-28Ardelyx, Inc.$1,395Research paymentCash or cash equivalentIBSRELA Drug, GASTROENTEROLOGYAN OPEN-LABEL LONG-TERM SAFETY STUDY OF TENAPANOR FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C2025
2025-05-16Alkermes, Inc.$1,062Research paymentCash or cash equivalentA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-05-16Alkermes, Inc.$1,062Research paymentCash or cash equivalentA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-05-12Takeda Pharmaceuticals U.S.A., Inc.$3,000Space rental or facility fees (teaching hospital only)Cash or cash equivalent2025
2025-05-09ABBVIE INC.$1,495Research paymentCash or cash equivalentRINVOQ Biological, IMMUNOLOGYStudy to Assess Adverse Events Change in Disease Activity and How Oral Upadacitinib Moves Through the Body of Pediatric 2025
2025-05-07Alkermes, Inc.$2,878Research paymentCash or cash equivalentA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-05-07Alkermes, Inc.$2,534Research paymentCash or cash equivalentA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-05-07Alkermes, Inc.$898Research paymentCash or cash equivalentA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-05-07Alkermes, Inc.$433Research paymentCash or cash equivalentA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-04-29Ardelyx, Inc.$500Research paymentCash or cash equivalentIBSRELA Drug, GASTROENTEROLOGYPhase II Dose ranging safety and efficacy studying IBS-C patients 6-12 years old2025
2025-04-28SANOFI US SERVICES INC.$1,955Research paymentCash or cash equivalentA double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic 2025
2025-04-26Organogenesis Inc.$3,000Space rental or facility fees (teaching hospital only)Cash or cash equivalentPURAPLY WOUND MATRIX Device, WOUND CARE2025
2025-04-25Siemens Medical Solutions USA, Inc.$500Research paymentCash or cash equivalentProBeam Proton Therapy System Device, OncologyFLASH Radiotherapy for the treatment of symptomatic bone metastases in the thorax.2025
2025-04-25Linde Gas & Equipment Inc.$330Space rental or facility fees (teaching hospital only)In-kind items and servicesREQNOXBOX-I Device, RESPIRATORY2025
2025-04-25Alkermes, Inc.$136Research paymentCash or cash equivalentA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-04-22Ardelyx, Inc.$1,229Research paymentCash or cash equivalentIBSRELA Drug, GASTROENTEROLOGYTEN 01-304 -SAFETY AND EFFICACY PHASE 03 IN 12-18 YEAR OLDS2025
2025-04-21Alkermes, Inc.$12,200Research paymentCash or cash equivalentA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-04-21Alkermes, Inc.$7,669Research paymentCash or cash equivalentA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-04-21Alkermes, Inc.$6,175Research paymentCash or cash equivalentA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-04-21Alkermes, Inc.$5,308Research paymentCash or cash equivalentA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-04-21Alkermes, Inc.$2,942Research paymentCash or cash equivalentA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-04-21Alkermes, Inc.$2,534Research paymentCash or cash equivalentA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-04-21Alkermes, Inc.$2,500Research paymentCash or cash equivalentA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-04-21Alkermes, Inc.$2,100Research paymentCash or cash equivalentA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-04-21Alkermes, Inc.$2,000Research paymentCash or cash equivalentA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-04-21Alkermes, Inc.$898Research paymentCash or cash equivalentA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-04-21Alkermes, Inc.$433Research paymentCash or cash equivalentA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-04-21Alkermes, Inc.$200Research paymentCash or cash equivalentA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-04-16Alkermes, Inc.$12,200Research paymentCash or cash equivalentA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-04-16Alkermes, Inc.$200Research paymentCash or cash equivalentA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-04-14SANOFI US SERVICES INC.$1,500Research paymentCash or cash equivalentA double-blind extension study to evaluate the long-term safety and tolerability of itepekimab in patients with chronic 2025
2025-04-08Ardelyx, Inc.$5,488Research paymentCash or cash equivalentIBSRELA Drug, GASTROENTEROLOGYTEN 01-304 -SAFETY AND EFFICACY PHASE 03 IN 12-18 YEAR OLDS2025
2025-04-07Alkermes, Inc.$2,500Research paymentCash or cash equivalentA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-04-07Alkermes, Inc.$2,100Research paymentCash or cash equivalentA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-04-07Alkermes, Inc.$2,000Research paymentCash or cash equivalentA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-04-03Alkermes, Inc.$259Research paymentIn-kind items and servicesAn Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of 2025
2025-04-03Alkermes, Inc.$119Research paymentIn-kind items and servicesAn Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of 2025
2025-04-03Alkermes, Inc.$113Research paymentIn-kind items and servicesAn Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of 2025
2025-04-03Alkermes, Inc.$82Research paymentIn-kind items and servicesAn Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of 2025
2025-04-03Alkermes, Inc.$77Research paymentIn-kind items and servicesAn Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of 2025
2025-04-03Alkermes, Inc.$77Research paymentIn-kind items and servicesA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025
2025-04-03Alkermes, Inc.$56Research paymentIn-kind items and servicesAn Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of 2025
2025-04-03Alkermes, Inc.$52Research paymentIn-kind items and servicesAn Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of 2025
2025-04-03Alkermes, Inc.$25Research paymentIn-kind items and servicesA Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Eva2025

The latest 200 records of 246.

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Champaign CountyUrbana city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Urbana, IL, county Champaign County, IL, state Illinois; placed by its city name.

MeasurePlace (city or town)
Urbana, IL
County
Champaign County, IL
State
Illinois
Population B0100339,341208,74112,694,798
Population, 2020 census P138,336205,86512,812,508
Median age B0100226.130.739.0
Under 18 B0100113.2%19.1%21.8%
65 and over B0100111.5%13.9%17.0%
Households B1100116,85685,4725,036,449
Foreign born B0500221.2%14.2%14.7%
Median household income B19013$45,346$63,683$83,390
Median family income B19113$86,209$100,396$106,018
Per capita income B19301$32,592$38,439$46,406
Poverty rate B1700128.0%19.1%11.8%
Unemployment rate B230254.7%4.3%5.8%
Civilian labor force B2302520,316104,8766,652,134
Mean commute (minutes) B0801314.216.927.8
Bachelor's degree or higher B1500356.7%46.2%37.8%
Housing units B2500119,22895,1155,457,452
Owner-occupied B2500337.3%54.0%67.1%
Renters B2500362.7%46.0%32.9%
Median home value B25077$184,900$211,500$263,300
Median gross rent B25064$972$1,051$1,274
White, not Hispanic B0300252.9%62.4%58.1%
Black B0300218.7%13.4%13.3%
Hispanic or Latino B0300210.1%8.3%18.8%
Asian B0300214.2%11.4%5.9%
American Indian and Alaska Native B030020.0%0.1%0.1%

Economy now FRED unemployment 4.6% in Sep 2026 (4.5% a year earlier); per capita personal income $78,987 in 2025, up 28% in five years (+3.1% after inflation); Unemployment rate: 5.7% in Sep 2016 to 4.6% in Sep 2026; low 3.6%, high 18.3% the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Urbana, IL.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.